The phase 2 ACTIV-2 findings (NCT30318759), investigating camostat for Mild-Moderate COVID-19 were discussed in this short interview with Dr Nikolaus Jilg (Massachusetts General Hospital, Boston, MA, USA). Camostat is a serine protease inhibitor, and prevents activation of the SARS-CoV-2 spike protein and blocks SARS-CoV-2 infection in vitro. Dr Jilg and colleagues studied the safety and antiviral and clinical efficacy of orally administered camostat in non-hospitalized adults with mild-moderate COVID-19.
The abstract entitled: ‘Camostat is not Effective for Mild-Moderate COVID-19 In A Phase II Trial of ACTIV-2’ (Abstract #105) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
Questions:
- What was the rationale for the use of camostat in the treatment of adults with mild-moderate COVID-19? (0:12)
- Could you give us a brief overview of the ACTIV-2/A5401 clinical trial? (1:19)
- What were the findings in terms of camostat efficacy and safety? (3:18)
- Why do you think camostat failed to show antiviral or clinical efficacy? (4:18)
- What are the implications of these findings for the evaluation of future therapies for COVID-19? (6:47)
Disclosures:Â Nikolaus Jilg has nothing to disclose in relation to this video interview
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022.
